| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Longeveron Inc. | Laromestrocel (lomecel-B) | Pediatric dilated cardiomyopathy (DCM) | Phase 2 | IND Clearance | Intravenous | Cardiology |
| Lumos Pharma Inc. | LUM-201 (OraGrowtH212) - (Switch) | Pediatric Growth Hormone Deficiency (PGHD) | Phase 3 | Trial Planned | Oral | Growth Disorder |
| Lumos Pharma Inc. | LUM-201 | Nonalcoholic Fatty Liver Disease (NAFLD) | Phase 2 | oral | Gastroenterology | |
| Lumos Pharma Inc. | LUM-201 - (OraGrowtH212) | Pediatric Growth Hormone Deficiency (PGHD) | Phase 2 | Data Released | Oral | Growth Disorder |
| Lumos Pharma Inc. | LUM-201 - (OraGrowtH210) | Pediatric Growth Hormone Deficiency (PGHD) | Phase 2 | Data Released | Oral | Growth Disorder |
| Lyell Immunopharma Inc. | Rondecabtagene autoleucel (ronde-cel) - (PiNACLE - H2H) | Aggressive Large B-Cell Lymphoma | Phase 3 | Ongoing | Intravenous infusion | Oncology |
| Lyra Therapeutics Inc. | LYR-210 - (ENLIGHTEN II) | Chronic rhinosinusitis | Phase 3 | Trial Discontinued | Intranasal | Respiratory |
| Lyra Therapeutics Inc. | LYR-210 - (ENLIGHTEN I) | Chronic rhinosinusitis | Phase 3 | Trial Discontinued | Intranasal | Respiratory |